Compare Johnson & Johnson (JNJ) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Norwegian Cruise Line Holdings Ltd — how do they compare? Johnson & Johnson trades at $249.28 (market cap $598.96B), while Norwegian Cruise Line Holdings Ltd trades at $19.46 (market cap $8.95B). The key difference: Johnson & Johnson is far larger — about 66.9× Norwegian Cruise Line Holdings Ltd's market cap, and Johnson & Johnson pays a 2.15% dividend while Norwegian Cruise Line Holdings Ltd pays none. Which is the better fit depends on your goals.
| JNJ | NCLH | |
|---|---|---|
Market Cap | $598.96B | $8.95B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $26.94 |
52-Week Low | $164.36 | $14.79 |
Enterprise Value | $631.90B | $23.92B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
Norwegian Cruise Line Holdings (NCLH) trades at $19.47, showing minimal daily movement with a 0.05% gain. The stock demonstrates strong fundamental momentum with three consecutive quarterly earnings beats and improving profitability metrics. Recent technical indicators show mixed signals with a bearish overall trend but neutral oscillators. The company maintains solid revenue growth, reaching $9.83 billion in 2025, while navigating significant capital expenditures for fleet expansion.
NCLH presents a compelling value opportunity with attractive valuation ratios (P/E: 15.69, P/S: 0.94) and strong analyst support (55.55% buy ratings). However, investors face risks from high debt levels ($13.1 billion total debt) and sensitivity to macroeconomic factors affecting travel demand. The upcoming Q2 2026 earnings report on July 30 represents a key catalyst for near-term price direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
